Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, strontium ranelate (Protelos®) cannot be endorsed for use within NHS Wales for the treatment of severe osteoporosis in adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. |
||
|
||
Medicine details |
||
| Medicine name | strontium ranelate (Protelos®) | |
| Formulation | 2 g granules for oral suspension | |
| Reference number | 1413 | |
| Indication | For the treatment of severe osteoporosis in adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. |
|
| Company | Servier Laboratories Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/11/2012 | |
| Date of issue | 13/11/2012 | |